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Epidermal growth factor receptor (EGFR) pathway
substrate 15 (Eps15) is a newly identified substrate
for protein tyrosine phosphatase N3 (PTPN3), which
belongs to the FERM-containing PTP subfamily com-
prising five members including PTPN3, N4, N13,
N14, and N21. We solved the crystal structures of
the PTPN3-Eps15 phosphopeptide complex and
found that His812 of PTPN3 and Pro850 of Eps15
are responsible for the specific interaction between
them. We defined the critical role of the additional
residue Tyr676 of PTPN3, which is replaced by
Ile939 in PTPN14, in recognition of tyrosine phos-
phorylated Eps15. The WPD loop necessary for
catalysis is present in all members but not PTPN21.
We identified that Glu instead of Asp in the WPE
loop contributes to the catalytic incapability of
PTPN21 due to an extended distance beyond pro-
tonation targeting a phosphotyrosine substrate.
Together with in vivo validations, our results provide
novel insights into the substrate specificity and
plasticity of FERM-containing PTPs.
INTRODUCTION
Signal transduction mediated by reversible tyrosine phosphory-
lation is an essential process for a diverse array of cellular activ-
ities (Tonks, 2006). This fundamental mechanism is controlled by
a balance of protein tyrosine kinases, protein tyrosine phospha-
tases (PTPs), and thousands of their substrates in cells. A prom-
inent feature of PTPs is to regulate both signal activation and
termination through the dephosphorylation of receptor tyrosine
kinases and their downstream substrates (Julien et al., 2011;
Tonks, 2006). Due to such critical functions in vivo, PTPs are
associated with various human diseases, including type 2 dia-
betes, immune disorders, and cancers (Julien et al., 2011; Mus-
telin et al., 2005; Ostman et al., 2006; Tonks, 2006).
It is known that PTPs execute their regulatory roles in cell
signaling through a sophisticated network of interaction with
specific substrates (Tiganis and Bennett, 2007; Tonks, 2006).Structure 23Accumulating evidences have demonstrated that substrate
specificity is the key for PTPs to control signal transduction pre-
cisely in vivo (Bentires-Alj and Neel, 2007; Elchebly et al., 1999;
Julien et al., 2007; Klaman et al., 2000; Salmeen et al., 2000). A
high level of the substrate specificity of PTPs can be determined
by the conserved catalytic domain (Salmeen et al., 2000; Sar-
miento et al., 1998), diverse regulatory domains (Francis et al.,
2011; Gray et al., 2003), restricted tissue distribution or subcellu-
lar localization (Haj et al., 2002), or various posttranslational
modification (PTM) events (Berman-Golan and Elson, 2007;
Dadke et al., 2007; Zheng et al., 2000). A classic example of sub-
strate specificity mediated by the PTP catalytic domain is the
recognition of the tandem tyrosinemotif (pYpY1162–1163) of the in-
sulin receptor kinase (IRK) by PTP1B. A structural study showed
that the pTyr1162 residue binds to the active site of PTP1B, and
the adjacent pTyr1163 fits within the secondary binding groove
(Salmeen et al., 2000). Based on this result, it was proposed
that a PTP that does not contain the consensus secondary bind-
ing groovemay lose its catalytic efficiency and specificity toward
IRK (Salmeen et al., 2000). In the case of HePTP, the substrate
specificity is primarily determined by the N-terminal kinase inter-
action motif (KIM) rather than its catalytic domain (Critton et al.,
2008; Francis et al., 2011, 2013). Additional studies suggested a
critical role of tyrosine phosphorylation at the C-terminal tail of
rPTPa and rPTPε in the activation of c-Src through the compet-
itive displacement mechanism (Berman-Golan and Elson, 2007;
Zheng et al., 2000). However, the aforementioned examples
represent only a small subset of PTPs with identified mechanism
of substrate specificity. To date, the molecular basis for sub-
strate recognition by many PTPs remains poorly characterized.
Obviously, structures of PTPs in complex with their substrates
at a high resolution are essential to delineate the underlying
mechanism that determines specific regulation of signaling path-
ways by PTPs.
Protein tyrosine phosphatase N3 (PTPN3/PTPH1) belongs to a
subfamily of five PTPs that contain an N-terminal 4.1 protein, ez-
rin, radixin, and moesin (FERM) plasma membrane-localization
domain and aC-terminal catalytic domain. PTPs in this subfamily
can be further divided into two types based on the presence of a
PDZ domain. Previous studies reported that PTPN3 is capable of
dephosphorylating several substrates (Han et al., 2000; Hou
et al., 2010; Zhang et al., 1999), including key regulators heavily
involved in the progression of human cancers (Hou et al., 2010;
Julien et al., 2011). In addition, we have recently shown that, 653–664, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 653
epidermal growth factor (EGF) receptor (EGFR) pathway sub-
strate 15 (Eps15) is an in vivo substrate of PTPN3 (Li et al.,
2014). Eps15 was identified to function as a scaffolding adaptor
that regulates endocytosis and trafficking of EGFR (van Bergen
En Henegouwen, 2009). It was also known that Eps15 is phos-
phorylated at Tyr850 (pTyr849 in human) following EGFR activa-
tion (Confalonieri et al., 2000). Nonetheless, the biological role of
Eps15 was not fully addressed until the demonstration of our
study that Tyr850 dephosphorylation of Eps15 by PTPN3 plays
a key role in promoting lipid raft-mediated endocytosis and lyso-
somal degradation of EGFR (Li et al., 2014), and consequently
downregulating cell proliferation and tumor growth in lung can-
cers (Li et al., 2014). These new findings collectively suggest
that the specific recognition of Eps15 as a substrate of PTPN3
is biologically relevant.
Because Eps15 does not contain any obvious protein interac-
tion motif that may bind to either the FERM domain or the PDZ
domain of PTPN3, we hypothesized that PTPN3-recognized
substrate specificity toward Eps15 is determined by the catalytic
domain. To elucidate the molecular insight, we have used crys-
tallography and enzyme kinetics to investigate how PTPN3 and
Eps15 form an enzyme-substrate complex. Our crystal structure
of the PTPN3 catalytic domain together with an Eps15 phospho-
peptide reveals an atypical, previously unknown binding orienta-
tion. With the complex formation between PTPN3 and Eps15 to
be a basis, we further extended our study to highlight key resi-
dues responsible for substrate recognition and catalysis of
members in this FERM domain-containing PTP subfamily.
RESULTS
Structure of PTPN3PTP-Eps15 Phosphopeptide
Complexes
A synthetic peptide that corresponds to the tyrosine phosphory-
lation segment of human Eps15 (Eps15846–854) was generated for
cocrystallization with the entire phosphatase domain (N3PTP) of
human PTPN3 (Figure 1A). To facilitate the formation of a stable
complex with tyrosine phosphorylated substrates, two essential
residues of PTPN3 for catalysis, D811 andC842,weremutated to
alanine and serine, respectively, according to our previous study
(Chen et al., 2014). Crystal structure of N3PTP D811A/C842S
mutants in complex with Eps15846–854 (hereafter designated as
the N3PTP D811A/C842S-Eps15
846–854 complex structure) was
phased bymolecular replacement and refined to 1.6 A˚ resolution
(Figure 1B; Table 1). The crystal structure revealed a 1:1 complex
inwhichEps15846–854was inserted into thePTPactive site pocket
forming the interaction with the pY, WPD, PTP and Q-loops
of PTPN3 (Figures 1B and 1C). Six residues (F846–S851) of
Eps15846–854 are clearly delineated in the electron density map
of theN3PTPD811A/C842S-Eps15
846–854 complex structure (Fig-
ure 1C). However, the electron density for residues 852–854 at
the C terminus of Eps15846–854 is invisible, suggesting a segment
with structural flexibility. To determine whether additional amino
acids are involved in the interaction with N3PTP, we synthesized a
lengthy Eps15 phosphopeptide with 23 residues (Eps15836–858)
and compared its binding affinity with PTPN3 with the original
short form of Eps15846–854. Based on the fluorescence polariza-
tion assay, the values of the dissociation constant, Kd, for
N3PTP D811A/C842S with the lengthy and short Eps15 phospho-654 Structure 23, 653–664, April 7, 2015 ª2015 Elsevier Ltd All rightspeptides are rather similar (Figure S1), suggesting that the resi-
dues between 846 and 854 are sufficient to accommodate the
active site of N3PTP.
TheAtypical BindingConformation of Eps15 IsMediated
by Its pTyr-Pro Motif
As revealed by the superposition of the N3PTP D811A/C842S-
Eps15846–854 complex structure with other known PTP-
phosphopeptide structures (Table S1), the C terminus of
Eps15846–854 shows an atypical orientation (Figure 1D). We
noticed that the first residue on the C terminus of the pTyr849 is
a proline (hereafter designated as P+1), which forms a pTyr-Pro
motif with the pY+0 as a trans isomer (Figures 1C and 1D). Due
to the unique characteristic of proline, in which the side chain is
cyclized into its nitrogen backbone, the psi and phi angles of
the peptide bond have fewer allowable degrees of rotation,
thus rendering limited conformation of P+1 (Figures 1C and 1D).
To gain insights into the role of proline in determining substrate
specificity, we resolved the structure of N3PTP D811A/C842S in
complex with a mutant form of Eps15 phosphopeptide in which
proline at the P+1 position was replaced by a valine (hereafter
designated as the N3PTP D811A/C842S-Eps15
846–854 P850V
complex structure, Table 1). We selected valine rather than other
residues because of the presence of valine at the P+1 position of
p38g, a known substrate of PTPN3 (Chen et al., 2014). The sub-
stitution of proline to valine induced a 3.8 A˚ shift of the pTyr-Pro
motif (Figures 1E and S2). As a result, an additional hydrogen
bond was formed with the carboxyl side chain of D678 on the
pY loop (Figure 1F), leading to a 1-fold decrease in Km compared
with thewild-type Eps15846–854 (Figure 1G). Clearly, the proline at
the P+1 position is necessary to maintain the atypical orientation
of the pTyr-Pro motif. In the absence of proline, Eps15 forms a
complex with PTPN3 in an orientation consistent with other
known structures (Critton et al., 2008; Phan et al., 2003; Salmeen
et al., 2000; Yu et al., 2011).
H812 of PTPN3 Is Required for the Recognition of Eps15
In addition to the pTyr-Pro motif, we observed an unusual
stacked-like interaction between the pyrrolidine ring of P+1 and
the imidazole ring of H812 (Figures 1C and 1F). The carbonyl
group of P+1 also formed hydrogen bonds with the side chain
of H812 and Q886 (Figure S3A), suggesting that these two
residues might be necessary for accommodating the atypical
orientation of the pTyr-Pro motif of Eps15. We notice that the
catalytically essential Q886 is conserved between PTPN3 and
PTP1B (Q262 in PTP1B, Figure 2A); however, the position of
H812 in PTPN3 is a phenylalanine (F182) in PTP1B (Figure 2A).
To test whether the presence of H812 is important to determine
substrate specificity, we measured the phosphatase activity
between two PTPs against Eps15 phosphopeptides. Our results
demonstrated that the catalytic domain of PTP1B could not
dephosphorylate Eps15846–854 or Eps15836–858 efficiently com-
pared with wild-type N3PTP (Figure 2B), supporting a critical
role of H812 in recognition of Eps15.
To examine whether H812 is necessary for determining sub-
strate specificity, we solved the structure of a D811A/H812F/
C842S/M883G mutant form of N3PTP, which acts as a surrogate
of the PTP1BPTP active site, in complex with Eps15
846–854 (Table
1), hereafter designated as the quadruple mutant-Eps15846–854reserved
Figure 1. Crystal Structure of the N3PTP D811A/C842S-Eps15
846–854 Complex
(A) Schematic showing the synthetic Eps15 and PTPN3 constructs used in this study.
(B) Cartoon representation of the N3PTP D811A/C842S-Eps15
846–854 complex. Eps15846–854 is highlighted as a light orange stick.
(C) Location of the bound Eps15846–854 on the active site of N3PTP. Residues of PTPN3 contributing to the interaction are shown as a stick. The electron density
shown corresponds to a simulated-annealing OMIT Fo  Fc map contoured at 3s.
(D) Superposition of the PTP-phosphopeptide complexes. PTPs are highlighted in white, Eps15846–854 is highlighted in light orange and other phosphopeptides
are highlighted in green cyan.
(E) Superposition of P850 (light orange stick) and P850V (light purple stick) Eps15846–854 from the two N3PTP D811A/C842S complexes.
(F) Highlight interactions between D678 and P850 or P850V containing Eps15846–854. Substitution of P850 at the P+1 position to a valine induced two hydrogen
bonds (blue dash line) with D678.
(G) Kinetic parameters of N3PTP using wild-type and P850V mutant of Eps15
846–854 as a substrate. Error bars represent the SEM for at least three independent
assays.
See also Figures S1 and S2, and Table S1.complex.We noticed that the introduction ofM883G substitution
increased the flexibility of the side chain of Q886, thus facilitating
interaction between F812 and the pTyr-Promotif (Figures 2C and
2D). In this complex structure, the phenyl side chain of F812 is
shifted 3.7 A˚ away from the active site pocket (Figures 2C and
2D). Instead of forming a stacked-like contact to P+1, the phenyl
side chain of F812 established a hydrophobic interactionwith the
main chain of E+3 (E852) and E+4 (E853) in Eps15 (Figure S3B).
When modeling the phenyl side chain of F812 to the position at
which the imidazole ring of H812 is located, we found a steric
repulsion with the carbonyl group of P+1 (Figure S3B). To avoid
this repulsion, F812 shifts away and the contacts to P+1 ofStructure 23Eps15 are lost, resulting in the formation of a much looser active
site pocket compared with the wild-type N3PTP (Figures 2E and
2F). As a consequence, there were a 6-fold increase in Km and
a 2-fold decrease in kcat when we substituted phenylalanine for
H812 in the kinetic assay of PTPN3 against Eps15 (Table 2).
Interestingly, this H812F mutant form of N3PTP behaved similarly
to the wild-type PTP1BPTP, which showed a 9-fold increase inKm
and a 3.6-fold decrease in kcat relative to thewild-type N3PTP (Ta-
ble 2) In the reciprocal experiment, we measured Eps15846–854
dephosphorylation catalyzed by the F182H mutant form of
PTP1BPTP. Clearly, the substitution of histidine for F182 led to
a 1-fold increase of kcat over its wild-type (Table 2), suggesting, 653–664, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 655











Eps15846–854 N3PTP Y676I N3PTP D811E
PDB ID 4RH5 4S0G 4RH9 4RHG 4RI4 4RI5

















a, b, g () 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Total observations 278,642 110,529 223,125 258,564 588,490 865,617
Unique, reflections 36,684 28,900 34,544 37,336 83,163 170,606
Completeness 99.8% (99.6%)a 99.0 (99.4)a 93.1% (97.3%)a 97.0% (100.0%)a 99.1% (97.7%)a 97.9% (90.3%)a
Rmerge
b 0.06 (0.36)a 0.068 (0.52)a 0.10 (0.60)a 0.04 (0.21)a 0.06 (0.54)a 0.04 (0.42)a
hI=sðIÞi 31.8 (4.8)a 15.0 (2.1)a 13.5 (3.4)a 39.8 (8.9)a 25.8 (3.5)a 37.1 (2.2)a
Multiplicity 7.6 (7.4)a 3.8 (3.9)a 6.5 (6.6)a 6.9 (7.3)a 7.1 (6.4)a 5.1 (4.5)a
Refinement Statistics
Rwork/Rfree (%)
c,d 17.4/20.4 18.2/22.9 19.5/22.6 18.3/20.9 16.3/18.9 15.9/17.3
No. of Non-H Atoms
Protein + ligand 2593 2303 2567 2593 5149 5611
Waters 261 139 206 212 543 873
Wilson B (A˚2) 14.7 19.5 18.0 17.9 20.6 15.4
Average B (A˚2) 20.2 28.8 26.0 25.2 27.4 23.3
RMSD bonds (A˚) 0.012 0.012 0.011 0.010 0.010 0.011
RMSD angles () 1.42 1.31 1.41 1.19 1.29 1.39
Ramachandran Plot
Favored (%)e 96.9 96.5 94.9 96.6 97.1 96.5
Outliers (%)e 0.3 0.4 0.3 0.3 0.3 0.5
aValues in parentheses refer to the highest resolution shell.
bRmerge =





l jFoj, where Fo and Fc are the observed and calculated structure-factor amplitudes for each reflection h.
dRfree was calculated with 10% of the diffraction data selected randomly and excluded from refinement.
eCalculated using Molprobabity.that a histidine instead of a phenylalanine at the 182 position im-
proves the substrate selectivity of PTP1B toward Eps15 (Figures
S3C and S3D). On the other hand, the minor decrease of Km in-
dicates that additional residues near the active site of PTP1B
might have impaired its ability to recognize Eps15.
Analysis of PTPN13 and PTPN14 within the FERM
Domain-Containing PTP Subfamily
Due to the presence of plasma membrane-localized FERM
domain, all members within this PTP subfamily may have the ac-
cess to tyrosine phosphorylated Eps15, which is in complex with
the receptor tyrosine kinase EGFR in cells. Using the knowledge
of structural insights that depict the substrate specificity deter-
mined by PTPN3, we investigated in the next phase of study
whether an additional four FERM domain-containing PTPs can
function as Eps15 phosphatases. Analysis of sequence align-
ment indicated that H812 is absolutely conserved throughout
the subfamily (Figures 3 and S4), highlighting a critical role of
this residue in substrate recognition among all five members.
In the case of PTPN4, we noticed that all necessary residues
around the active site for catalysis are conserved with PTPN3656 Structure 23, 653–664, April 7, 2015 ª2015 Elsevier Ltd All rights(Figure 3). In addition, the overall sequence identity inside the
catalytic domains of PTPN3 and PTPN4 reaches 62%. These
features suggest that substrate specificity between the two
phosphatases may be determined by regions outside the cata-
lytic domain, and thus, the detailed investigation is beyond the
scope of our present study. PTPN13 has been reported to be a
PTP1B-like enzyme (Villa et al., 2005) due to the presence of
G2449 (Figure 3) in the secondary binding pocket (G259 in
PTP1B, shown in Figure 2A). However, PTPN13 binds to
Eps15846–854 more strongly than PTP1B (Table 3, compared
with Table 2), largely because of the unique H2379 responsible
for substrate recognition (Figure 3). The other difference that
we noticed is an aspartic acid (D2380) in PTPN13 instead of a
glycine residue in PTPN3 inside the WPD loop (Figure 3). The
presence of an additional aspartic acid suggests that the side
chain of H2379 in PTPN13 might interact with the side chains
of D2378 and D2380. Such interaction likely causes a perturba-
tion of H2379, rendering this particular residue unable to form a
stable stacked-like contact to Eps15846–854. As a result, we
observed a 3-fold increase in Km of the wild-type PTPN13PTP
compared with N3PTP (Table 3).reserved
Figure 2. Comparison of H812 and F812 in the Recognition of Eps15846–854
(A) Sequence alignment of PTPN3 and PTP1B showing the pY loop, WPD loop, PTP loop, and Q-loop. Conserved residues are highlighted in green, and key
variable residues, F182 and H812, are highlighted in red. Sequence alignment was generated using CLUSTALW from Network Protein Sequence Analysis using
default parameters (Combet et al., 2000).
(B) Phosphatase activity of the wild-type N3PTP and PTP1BPTP toward two different Eps15 phosphopeptide substrates. The assay was performed using 10 nM of
protein with 50 mM of Eps15 phosphopeptides. Error bars represent the SEM for at least three independent assays.
(C) Highlight of the active site of the N3PTP D811A/C842S-Eps15
846–854 complex structure (white) superposed with the quadruple mutant-Eps15846–854 complex
structure (green cyan).
(D) Superposition rotated 90 around the horizontal axis of (C) to show the hydrogen bonds of the carbonyl group of P+1 to the side chains of H812 and Q886
(indicated as brown dashed lines).
(E) Molecular surface of the N3PTP D811A/C842S-Eps15
846–854 complex structure highlights H812 (blue).
(F) The quadruple mutant-Eps15846–854 complex structure highlights F812 (orange).
See also Figure S3.In the case of PTPN14, the noticeable difference is a substitu-
tion of tyrosine in the pY loop with an isoleucine (Figure 3). Pre-
vious study has found that the substitution of Y46 with alanine inStructure 23PTP1B resulted in a 380-fold increase in Km using pNPP as a
substrate (Sarmiento et al., 1998). Consistently, in the absence
of this critical tyrosine, the wild-type PTPN14PTP is catalytically, 653–664, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 657
Table 2. Kinetic Parameters of PTP1BPTP, N3PTP, and the
Reciprocal Mutants Using Eps15846–854 as a Substrate
Enzyme kcat (s




Wild-type 17.3 ± 1.2 43.8 ± 3.3 394 ± 8.2
H812F 8.9 ± 0.4 260.3 ± 15.3 34 ± 2
PTP1BPTP with Eps15
846–854
Wild-type 4.8 ± 1.1 387.9 ± 11.7 12 ± 2.6
F182H 8.1 ± 1.9 317.2 ± 10.9 34 ± 2.0inactive when four structurally characterized phosphopeptides
were used as the substrate in the assay (Figure 4A; Table 3).
Interestingly, the Y676I mutant form of N3PTP also lost the cata-
lytic activity completely (Figure 4A). To further improve our
understanding of the necessary role of this tyrosine residue in
catalysis, we solved the structure of the N3PTP Y676I mutant in
complex with sodium orthovandate (Table 1), hereafter desig-
nated as the N3PTP Y676I mutant structure. The electron density
of I676 and sodium orthovandate is well defined (Figure S5). Us-
ing the phosphopeptide Eps15846–854 to model the interaction
with the active site pocket of the N3PTP Y676I mutant structure,
we found that the Cg2 atom of I676 is too close toward the back-
bone amide nitrogen of pY+0 (Figures 4B and 4C), likely causing a
steric repulsion.We propose that such repulsive force is unfavor-
able for the phosphotyrosine substrate to fit into the deep narrow
active site of PTP, leading to a loss of enzymatic activity.
UniqueStructural Feature of PTPN21Reveals aKeyRole
of the Glutamic Acid in the WPE Loop
It has been well understood that a conserved aspartic acid,
which functions as a general acid for nucleophilic attack on the
substrate in the first step of catalysis, must appear in the WPD
loop among active PTPs. However, this critical residue in
PTPN21 is substituted with a glutamic acid, thus resulting in a
WPE loop instead (Figure 3). Because of the similarity of chemi-
cal characters between aspartic acid and glutamic acid, the
WPE loop in PTPN21 might preserve key features for catalysis.
On the other hand, a lengthier side chain of glutamic acid
compared with aspartic acid could make a unique microenviron-
ment constructed by the WPE loop. With such uncertainties, it
is difficult to predict whether PTPN21 is able to recognize
Eps15846–854 as a substrate. To address this question, we
characterized the WPE loop using PTPN3 as a model. The as-
partic acid 811 was replaced by a glutamic acid on the
backbone of C842S mutant form of N3PTP. The phosphopeptide
Eps15846–854 was complexed with this N3PTP D811E/C842S
mutant protein, and then subjected to X-ray crystallography.
Examining the details of our structure (Table 1), hereafter desig-
nated as the N3PTP D811E/C842S-Eps15
846–854 complex struc-
ture, we observed clear density of the phosphopeptide and
WPE loop in a close conformation (Figure S6), which to our
knowledge has never been reported previously.
We noticed that the side chain of E811 in the N3PTP D811E/
C842S-Eps15846–854 complex structure is shifted toward K753
in the E-loop (Figures 5A and 5B). Remarkably, the presence of
E811 extended protonation distance targeting the P-O bond of
pY+0 to 4.7 A˚ compared with 2.5 A˚ in the N3PTP D811A/C842S-658 Structure 23, 653–664, April 7, 2015 ª2015 Elsevier Ltd All rightsEps15846–854 complex structure in which D811 was modeled
(Figures 5A and 5B). If the side chain of E811 moved closer to-
ward the P-O bond, a steric clash would occur due to an extra
methylene group in the glutamic acid. Interestingly, the imidazole
ring of H812 in the N3PTP D811E/C842S-Eps15
846–854 complex
structure exhibits an alternative conformation that shifts 2.3 A˚
outward from the active site, likely due to the perturbation
caused by E811 (Figure 5A), which led to a 3-fold increase in
the Km of the D811E mutant (Table 3). Moreover, our kinetic
study indicated that substitution of D811 with glutamic acid in
PTPN3 resulted in an 870-fold reduction of kcat (Table 3). Consis-
tently, we were unable to detect any activity for the WPE loop-
containing constructs, no matter whether pNPP (Figure 5C) or
Eps15846–854 (Figure 5D) was used as a substrate in the phos-
phatase activity assay. Interestingly, once the glutamic acid in
the WPE loop was replaced by an aspartic acid, the E1067D
mutant form of PTPN21PTP exhibited a significantly higher level
of phosphatase activity compared with its wild-type counterpart
(Figures 5C and 5D). The data demonstrate that the WPE loop is
a key region responsible for the catalytic inertness of PTPN21.
Our results demonstrated that the glutamic acid of the WPE
loop is located in an unfavorable position, so it cannot act as a
general acid in the first step of the dephosphorylation process.
We then investigated whether this glutamic acid forms a
hydrogen bond with the nucleophilic water molecule, similar to
how the aspartic acid of theWPD loop functions in the hydrolysis
step during substrate dephosphorylation. For this, we crystal-
lized the D811E mutant form of N3PTP in the presence of a 1-
fold molar excess of sodium orthovanadate. The structure of
the N3PTP D811E single mutant (Table 1), hereafter designated
as the N3PTP D811E mutant structure, solved at 1.25 A˚ reveals
an unusual trigonal planar shape of electron density around the
thiol group of C842 (Figure 5E). Different from the trigonal bipyr-
amidal shape density of orthovanadate in the N3PTP Y676I
mutant structure, the density shown in the N3PTP D811E mutant
structure is likely to be ametavanadate (Figure 5E). Typically, the
orthovanadate is formed due to attack of the nucleophilic water
positioned by catalytically essential glutamine and aspartic acid
of the Q-loop and WPD loop, respectively (Pannifer et al., 1998)
(Figure 5F). However, we observed that E811 in the N3PTP D811E
mutant is out of the position to facilitate Q886 in coordination of
the nucleophilic water molecule, thus explaining why a metava-
nadate molecule was formed (Figure 5G). Collectively, our struc-
tural findings provide an underlying mechanism of how the WPE
loop of PTPN21 is incapable of coordinatingwith the nucleophilic
water molecule during the dephosphorylation process.
H812 and D811 in PTPN3 Are Essential for Regulating
Eps15-Dependent EGFR/MAPK Signaling In Vivo
The critical roles of H812 and D811 in substrate recognition
and efficient catalysis of PTPN3-mediated Eps15 dephosphory-
lation have been clearly delineated by structural approaches
(Figures 2 and 5) and enzyme kinetic analyses (Tables 2 and 3).
We next tested whether the presence of these two residues
is essential for PTPN3 to regulate Eps15-dependent EGFR
signaling in cultured cells. Transfection of human embryonic
kidney HEK293T cells with the wild-type PTPN3 significantly
decreased EGF-induced Y849 phosphorylation of Eps15,
whereas ectopic expression of the D811E or H812F mutantreserved
Figure 3. Sequence Alignment of FERM Domain-Containing PTPs against PTP1B Showing the pY Loop, WPD Loop, PTP Loop, and Q-Loop
Conserved residues are highlighted in green and labeled on top. Key variable residues are highlighted in red. Key residues discussed in this study are indicated
with an arrow. Sequence alignment was generated using Clustal W from Network Protein Sequence Analysis using default parameters (Combet et al., 2000).
See also Figure S4.form of PTPN3 did not affect the Y849 phosphorylation levels of
Eps15 (Figure 6A). Furthermore, in the H1975 line derived from
human non-small-cell lung cancer, in which the wild-type form
of PTPN3 could downregulate EGFR signaling via dephosphory-
lating Eps15 (Li et al., 2014), we found that ectopic expression of
the D811E or H812F mutant form of PTPN3 failed to reduce the
level of endogenous EGFR and the phosphorylation of mitogen-
activated protein kinase (MAPK) in response to EGF stimulation
(Figures 6B and 6C). These results suggest that, when expressed
in H1975 cells, both mutant forms of PTPN3 were incapable of
dephosphorylating Eps15 efficiently, consequently leading to
the accumulation of EGFR and constitutive activation of the
downstream MAPK signaling pathway.
DISCUSSION
We investigated the molecular basis that determines the specific
interaction between PTPN3 and Eps15, both of which function
coordinately to regulate endocytosis and degradation of EGFR.
The structural analysis revealed critical roles of the H812 in
the phosphatase domain of PTPN3 and the pTyr-Pro motif of
Eps15 responsible for the formation of the PTPN3-Eps15 com-
plex. We showed that the stacked-like interaction drives the
binding of H812 specifically to the P+1 position of the pTyr-Pro
motif. The substitution of H812 with phenylalanine in PTPN3 re-
sulted in a loss of Eps15 recognition without significantly altering
its catalytic activity, confirming the substrate specificity deter-
mined by this particular residue. Although the conserved His res-
idue is present in all five PTPs belonging to the same subfamily
with a FERM domain, diversities in the pY loop, WPD loop, and
Q-loop occur among these members. We demonstrated an
essential role of the tyrosine residue in the pY loop of PTPN3
for a robust interaction with specific substrates. PTPN14 that
has an isoleucine instead of a tyrosine in the pY loop loses the
binding affinity to Eps15. A combination of structural study and
enzymatic kinetic analysis further indicates that an aspartic
acid (D811 in PTPN3) in the WPD loop is absolutely required
for PTP-mediated substrate dephosphorylation. The presence
of a glutamic acid instead of an aspartic acid in the WPE loop
renders PTPN21 to retain its ability for substrate recognition.
However, this glutamic acid located in the active site of the
phosphatase domain is structurally unfavorable to function as
a general acid, thus significantly reducing the catalytic activity
of PTPN21. Further in vivo evidence depicted that both theStructure 23H812F and D811E mutant forms of PTPN3 cannot regulate the
Eps15-dependent EGFR/MAPK signaling pathway in response
to EGF stimulation, validating the structural insights demon-
strated in our study. In addition to Eps15, we have identified
seven phosphotyrosine proteins that share a common pTyr-
Pro motif (Table S2). New findings shown in the current work
open an avenue toward delineating specific recognition of other
putative substrates by PTPN3.
Our data suggest that the conserved histidine residue located
in the WPD loop of FERM domain-containing PTPs plays a key
role in recruiting Eps15 as a substrate. However, the presence
of this histidine alone may not be sufficient enough to determine
the substrate specificity of PTPs. Recent studies have used the
approach of peptide library screening to search for sequence
specificity that pairs a PTP and its substrate (Barr et al., 2009;
Ren et al., 2011). One report using such an approach aimed to
characterize the substrate specificity of Lyp, a PTP containing
a histidine in the WPD loop (Yu et al., 2011). Interestingly, the
study identified an overall preference for acidic residues instead
of a proline at the P+1 position of the potential substrates of Lyp
(Yu et al., 2011). This finding suggests that, even although a given
PTP contains a histidine residue in the WPD loop, it may not
recognize Eps15 as a substrate. We propose that a complete
interaction network formed by not only the histidine but also
other key residues in the phosphatase domain is required to
perfectly coordinate with the pTyr-Pro motif of Eps15.
Three residues, including M883 in the Q-loop, Y676 in the pY
loop, and D811 in theWPD loop, which are present in PTPN3 but
are replaced by various amino acids among other PTPs in the
same subfamily, were investigated for their roles in determining
substrate specificity. We showed that the binding affinity of
PTPN13PTP for Eps15
846–854 is weaker than N3PTP. A possible
reason for that is the presence of G2449 in the Q-loop of
PTPN13, instead of M833 at the same position in PTPN3. Inter-
estingly, a previous study suggested that G2449 in the Q-loop
facilitates the formation of a secondary binding pocket, thus pro-
moting the preference of dual phosphorylated substrates for
PTPN13 (Villa et al., 2005). Nonetheless, the impact of this partic-
ular substitution to the determination of substrate specificity
among PTPs requires further investigation.
To date, the structural basis for substrate recognition of
PTPN14 has been poorly understood (Wadham et al., 2003;
Zhang et al., 2013). PTPN14 is the only nonreceptor PTP that con-
tains an isoleucine instead of an aromatic residue in the pY loop, 653–664, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 659
Figure 4. Y676ISubstitutionCausesStericRepulsionwithEps15846–854
Table 3. Kinetic Parameters of D811E, Y676I and FERM Domain-
Containing PTPs Using Eps15846–854 as a Substrate
Enzyme kcat (s
1) Km (mM) kcat/Km 3 10
3 (M1 s1)
N3PTP
Wild-type 17.3 ± 1.2 43.8 ± 3.3 394 ± 8.2
Y676I ND ND 
D811E 0.019 ± 0.002 131.4 ± 1.6 0.10 ± 0.01
PTPN13PTP
Wild-type 14.0 ± 0.5 140.3 ± 8.0 100 ± 2
PTPN14PTP
Wild-type ND ND –
ND, no phosphatase activity detected.(Sarmiento et al., 1998). Examining the structural insights of the
N3PTP Y676I mutant, we observed a close proximity between
the methyl side chain of I676 and the main chain of pY+0 in the
substrate, indicating a high degree of difference in the substrate
recognition process between PTPN3 and PTPN14. Importantly,
a number of phosphoproteins without sequence similarity to
Eps15, such as b-catenin (Wadham et al., 2003), YAP (Liu et al.,
2013), and p130Cas (Zhang et al., 2013), were found to be poten-
tial substrates of PTPN14. Additional studies are needed to reveal
whether the unique structure of I939 in the pY loop plays a key
role in coordinating with specific substrates of PTPN14.
Among nonreceptor PTPs, PTPN21 and PTPN23 are the only
two members that have a WPE loop instead of a WPD loop. Us-
ing structural approaches, we demonstrated how the substitu-
tion of aspartic acid with glutamic acid causes a loss of proton
donation to substrate, thus providing the underlying mechanism
of catalytic inertness of PTP21 and PTPN23 reported previously
(Barr et al., 2009; Gingras et al., 2009). On the other hand, many
receptor PTPs (rPTPs) have aWPE loop in their membrane-prox-
imal domain (D2 domain). In fact, it has been reported that D2
domains of these rPTPs exhibit low or no catalytic activity
(Andersen et al., 2001; Streuli et al., 1990; Wang and Pallen,
1991), even although their overall three-dimensional fold shows
similar features to the catalytically active D1 domain (Streuli
et al., 1990). Clearly, our results provide the first structural basis
that rationally explains why those WPE loop-containing D2 do-
mains in rPTPs are catalytically inert.
In conclusion, our findings not only identify key residues in
the phosphatase domain that determine specific interaction be-
tween PTPN3 and Eps15 but also provide structural interpreta-
tions on how the substrate plasticity is achieved among FERM-
containing PTPs. The molecular insights presented in this study
will enable rational drug design to treat human diseases that are
associated with dysfunction of these five PTPs.(A) Phosphatase activity of the wild-type PTPN14PTP, N3PTP, and the Y676I
mutant of N3PTP using four different phosphopeptides as substrate. The assay
was performed using 20 nM protein with 200 mM phosphopeptides. Error bars
represent the SEM for at least three independent assays.
(B and C) (B) Highlight of Y676 from the N3PTP D811A/C842S-Eps15
846–854
complex and (C) I676 from the N3PTP Y676I mutant structure. For clarity,
Eps15846–854 in (C) was modeled from the N3PTP D811A/C842S-Eps15
846–854
complex. The sphere represents the van der Waals radius of each atom of
Y676, I676, and themain chain of pY+0. The schematic illustrates the side chain
atoms in close contact, shown in the top left corner.
See also Figure S5.EXPERIMENTAL PROCEDURES
Plasmid Construction and Site-Directed Mutagenesis
PCR fragments of N3PTP (residues 628–909), PTP1BPTP (residues 1–320),
PTPN4PTP (residues 611–926), PTPN13PTP (residues 2163–2467), PTPN14PTP
(residues 886–1187), and PTPN21PTP (residues 872–1174) were amplified
from the full-length human PTPN3-, PTP1B-, PTPN4-, PTPN13-, PTPN14-,
and PTPN21-encoded genes, respectively. All amplified gene products
were ligated into an N-terminal His-tag pMCSG7 vector using ligation inde-
pendent cloning (Stols et al., 2002). Site-directed mutagenesis was used to660 Structure 23, 653–664, April 7, 2015 ª2015 Elsevier Ltd All rights reserved
Figure 5. Effect of the D811E Substitution on the Substrate Recognition
(A) Close view of the N3PTP D811E/C842S-Eps15
846–854 complex structure (green cyan) active site pocket superposed with the N3PTP C842S mutant structure
(PDB accession code 4QUN).
(B) Superposition rotated 45 around the horizontal axis of (A). Protonation distance of the tyrosyl leaving group of the substrate by the D811/E811 is 2.7 A˚ and
4.7 A˚, respectively (blue dashed line).
(C) Phosphatase assay of wild-type (N3PTP wt) and D811E mutant of N3PTP, wild-type (N21PTP wt) and E1067D mutant of PTPN21PTP using pNPP.
(D) Eps15846–854 as the substrate. For the pNPP assay, 800 nM protein wasmixed with 2mM pNPP substrate. For the phosphopeptide assay, 200 nM protein and
200 mM Eps15846–854 were used. Error bars represent the SEM for at least three independent assays.
(E) Close view of the N3PTP D811E mutant structure (light orange) active site pocket superposed with the N3PTP D811E/C842S-Eps15
846–854 complex structure.
The trigonal planar shape of metavanadate is shown. The electron density corresponds to a simulated-annealing OMIT Fo  Fc map contoured at 3s.
(F) The proposal mechanism of orthovanadate formation in the active site of PTPN3.
(G) The formation of a metavanadate in the active site of PTPN3 D811E mutant.
See also Figure S6.generate specific mutations (Stratagene). All primers used in the mutagen-
esis study are listed in Table S3. All of the mutations were confirmed using
DNA sequencing.
Cell Culture, Transfection, Immunoprecipitation, and
Immunoblotting
For immunoprecipitations, HEK293T or H1975 non-small-cell lung cancer cells
that were transiently transfected with the indicated plasmids (wild-type,
D811E, or H812F) were scraped from dishes into lysis buffer containing
50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP40, 0.25% sodium deoxycho-
late, 1 mM EDTA, 10mMNaF, 2 mMNa3VO4 1 mMPMSF, and protease inhib-
itor cocktail (Roche). For HEK293T cells, lysates were immunoprecipitated
with an anti-Flag antibody and protein G-Sepharose beads (GE Healthcare)
at 4C for 3 hr. These beads were washed three times in lysis buffer before
the addition of a DTT-containing sample buffer and boiling for 5 min. After res-
olution using SDS-PAGE, the immunoprecipitates were subjected to western
blot analysis as previously described (Chen et al., 2012).
Protein Expression and Purification
His-tagged PTP constructs were expression in Escherichia coli, and purified
by Ni-NTA resin (GE Healthcare) and size-exclusion chromatography. Addi-
tional details can be found in the Supplemental Experimental Procedures.Structure 23Crystallization and Data Collection
Protein crystallization trials were performed in 96-well plates using the sitting-
drop vapor diffusion method at 20C. In general, N3PTP D811A/C842S, N3PTP
D811A/H812F/C842S/M883G, or N3PTP D811E/C842S was mixed with 10-fold
molar excess of Eps15846–854 solution to a final concentration of 8.5 mg/ml.
Rod needle-shaped crystals were obtained from 1.5 ml of protein-peptide
mixture and 0.5 ml of reservoir consisting of 100 mM Tris-HCl (pH 8.5),
21% PEG 8000, and 5% glycerol. N3PTP D811A/C842S in complex with
Eps15846–854 P850V was crystallized under the same conditions as described
for Eps15846–854, except that 26% PEG 8000 was used. To grow crystals of
the N3PTP D811E mutant, a mixture containing a 9.5-fold molar excess of the
Eps15 phosphopeptide plus a 0.5-fold molar excess of sodium orthovanadate
was added to the N3PTP D811E mutant protein. The final concentration used
for crystallization was 8.5 mg/ml. The best crystals of the N3PTP D811E mutant
were grown under conditions similar to those used for the protein-peptide com-
plex. Prior to data collection, all crystals excepted for N3PTP D811A/C842S in
complex with Eps15846–854 P850V were flash frozen in cryoprotectant solution
consisting of 100 mM Tris-HCl (pH 8.5), 21% PEG 8000, and 8% glycerol.
Crystallization of the N3PTP Y676I mutant with a WPD loop in the close
conformation was achieved by adding 5-fold molar excess of sodium orthova-
nadate to the purified N3PTP Y676Imutant to a final concentration of 8.0mg/ml.
The best crystals were grown in conditions consisting of 100 mM Tris-HCl (pH, 653–664, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 661
Figure 6. Effect of theWild-Type andMutants of PTPN3 on the Tyro-
sine Phosphorylation Levels of Eps15 upon EGF Stimulation
(A) Immunoprecipitation western analysis of wild-type, D811E, and H812F
PTPN3 in HEK293T cells. Expression of wild-type PTPN3 markedly abolished
EGF-induced tyrosine phosphorylation of Eps15 but not the D811E or the
H812F mutants.
(B and C) Overexpression of D811E (B) or H812F (C) PTPN3 in H1975 lung
cancer cells rescued endogenous EGFR protein levels and EGF-induced
MAPK activation. The data shown are representative of three independent
experiments.7.5), 25% PEG 8000. Crystals of the N3PTP Y676I mutant were flash frozen in a
cryoprotectant solution consisting of 100 mM Tris-HCl (pH 7.5), 26% PEG
8000, and 5% glycerol.
Structure Determination
X-Ray diffraction data of all six crystal structures were collected at the
National Synchrotron Radiation Research Center BL-15A1 beamlines at a662 Structure 23, 653–664, April 7, 2015 ª2015 Elsevier Ltd All rightswavelength of 1.0 A˚ and recorded with a Rayonix MX300HE charge-coupled
device area detector. Reflections were indexed, integrated, and scaled
using HKL2000 (Otwinowski and Minor, 1997). The N3PTP D811A/C842S-
Eps15846–854 complex structure was determined by molecular replacement
using Phaser (McCoy et al., 2007) and the wild-type N3PTP structure (PDB
ID 2B49) as the search model. The best solutions for the other complexes
were obtained using the N3PTP D811A/C842S-Eps15
846–854 complex struc-
ture as the search model (Table 1). The initial electron density map after Phe-
nix refinement (Adams et al., 2010) guided the location of the PTP domain and
Eps15846–854. Waters were added using the ordered solvent process and the
default parameters in Phenix were refined and manually checked from Coot
(Emsley and Cowtan, 2004). The refined model was manually adjusted using
Coot guided by Fo Fc differencemaps. Coordinates for glycerol, sodium or-
thovandate, and sodium metavanadate were generated using LIBCHECK
from Coot. The quality and geometry of the refined structures were evaluated
usingMolProbity (Chen et al., 2010). Data collection and refinement statistics
are summarized in Table 1. Root-mean-square deviation (RMSD) was calcu-
lated using Dali (Holm and Rosenstrom, 2010) and molecular figures were
generated using PyMOL.Fluorescence Polarization
Fluorescence polarization assays were performed in a 30 ml volume con-
taining 10 nM of N-terminal fluorescein isothiocyanate (FITC)-labeled
Eps15 phosphopeptides and N3PTP D811A/C842S ranging from 8 mM to
0.488 nM in buffer containing 50 mM Tris-HCl (pH 7.4) and 150 mM
NaCl. Reactions were repeated three times in 384-well black microplates
and measured using a SpectraMax Paradigm plate reader (Molecular De-
vices) with excitation and emission wavelengths of 485 nm and 535 nm,
respectively. Data were analyzed and plotted using Prism version 6.0d
(GraphPad software).pNPP Assay
pNPP assays were performed in a 50 ml volume comprising 50 mM Tris-HCl
(pH 7.4), 50 mM NaCl, and 1–2 mM pNPP with varied concentrations of
PTPs ranging from 50 nM to 800 nM. The reactions were incubated at 30C
for 10 min at 405 nm using a PowerWave XS2 microplate reader (BioTeK).
The absorbance was converted to the amounts of p-nitrophenol produced us-
ing a standard curve of known amounts. Phosphatase activity was calculated
from the three biological replicates.Phosphopeptide Assay and Kinetic Analysis
For the phosphopeptide assay, 200 ml of reaction was set up containing 5–
20 nM of purified proteins (excepted for the PTPN3PTP D811E mutant) in
an assay buffer consisting of 50 mM Tris-HCl (pH 7.4), 50 mM NaCl, and
0–500 mM of indicated phosphopeptide. To measure the phosphatase activ-
ity of N3PTP D811E mutant, 2 mM purified protein was added. After 2–10 min
incubation at 30C, the reactions were terminated by adding 30 ml of phos-
phate reagent from the phosphate colorimetric assay kit (Biovision) following
the manufacturer’s instructions. The absorbance was measured at 650 nm,
using a PowerWave XS2 microplate reader (BioTeK). Conversion of absor-
bance to the amounts of phosphate production was calculated using the
standard curve of known phosphate concentrations. The data were fitted
using a nonlinear curve and the kinetics parameters, Km and kcat, were calcu-
lated from the Michaelis-Menten equation using Prism version 6.0d (Graph-
Pad software). All points in enzyme kinetics were measured in three repli-
cates and the experiments were repeated three times to obtain consistent
results.ACCESSION NUMBERS
The atomic coordinates and structure factors for the N3PTP D811A/C842S-
Eps15846–854 complex, N3PTP D811A/C842S-Eps15
846–854 P850V complex,
quadruple mutant-Eps15846–854 complex, N3PTP D811E/C842S-Eps15
846–854
complex, N3PTP Y676I mutant, and N3PTP D811E mutant have been deposited
in the RCSB PDB under accession codes 4RH5, 4S0G, 4RH9, 4RHG, 4RI4,
and 4RI5, respectively.reserved
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